Keyword: PARP

Study : Racial and ethnic differences in genetic testing among young breast cancer survivors

Relevance: High

Strength of Science: Medium-High

View Related Clinical Trials

Most relevant for: Women diagnosed with breast cancer at age 50 or younger

Genetic testing is recommended for most women who are diagnosed with breast cancer at age 50 or younger.  In this study of young women with breast cancer, while the rates of genetic testing  did not differ, the rates of women testing positive for an inherited mutation associated with breast cancer did vary between racial and ethnic groups. (2/27/20)

Este artículo está disponible en español.

Study : Second surgery may not benefit women with recurrent ovarian cancer

Relevance: High

Strength of Science: High

Research Timeline: Post Approval

Most relevant for: Women with recurrent ovarian cancer

Many women who have recurrent ovarian cancer have a second surgery. A new study suggests that women with platinum sensitive cancers who get chemotherapy alone may do as well as or better than women who have surgery followed by chemotherapy. (1/21/20)

Study : Niraparib increases progression-free survival in patients with newly diagnosed ovarian cancer

Relevance: High

Strength of Science: High

Research Timeline: Human Research

View Related Clinical Trials

Most relevant for: Women newly-diagnosed with ovarian cancer

This study looked at the effectiveness and safety of niraparib (Zejula), a PARP inhibitor, as maintenance therapy in newly diagnosed ovarian cancer patients who had a response to chemotherapy. (11/5/19)

Study : Research on the PARP inhibitor talazoparib (Talzenna) for early-stage breast cancer is promising

Relevance: Medium-High

Strength of Science: Medium-High

Research Timeline: Human Research

Most relevant for: People with early stage breast cancer who have an inherited BRCA mutation

The PARP inhibitor talazoparib (Talzenna) has been useful for treatment of advanced or metastatic breast cancer for patients with BRCA mutations. A preliminary study showed that the majority of patients who took talazoparib alone before surgery for early-stage breast cancer had effective treatment and manageable side effects. Expanded clinical trials are in progress to verify this result. (10/4/19)

Study : Inherited mutations in metastatic breast cancer patients

Relevance: Medium-High

Strength of Science: Medium

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: People with metastatic breast cancer

Recent research shows that a significant portion of patients with metastatic breast cancer have harmful mutations in a gene associated with hereditary breast cancer and increased breast cancer risk. (9/26/19)

Study : Results from the POLO trial: Olaparib may delay cancer progression in metastatic pancreatic cancer patients with BRCA mutations.

Relevance: High

Strength of Science: High

Research Timeline: Human Research

View Related Clinical Trials

Most relevant for: People diagnosed with pancreatic cancer who have a BRCA mutation

Note: On 12/27/19, the FDA approved olaparib for treatment of pancreatic cancer in people with a BRCA mutation based on the results of the POLO study.

The POLO clinical trial looks at whether the PARP inhibitor olaparib improves outcomes for those with metastatic pancreatic cancer after platinum-based chemotherapy.  (7/3/19) 

Guideline : Breast surgeons recommend genetic testing for all breast cancer patients

Relevance: Medium-High

Research Timeline: Post Approval

Most relevant for: Anyone diagnosed with breast cancer

The American Society of Breast Surgeons published statement on genetic testing for hereditary breast cancer on February 10, 2019. It includes recommendations about who should be tested. Among these is the recommendation that all breast cancer patients get genetic testing, as well as women who do not have breast cancer but fit the National Comprehensive Cancer Network (NCCN) guidelines. (3/25/19)